Ownership and insider activity for Candel Therapeutics, Inc. (CADL): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma.
Price
| Price | $11.02 |
| Market Cap | $807M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-10 | Tak Paul Peter | M-Exempt | 125,000 | $194K |
| 2026-09-10 | Tak Paul Peter | M-Exempt | 125,000 | $194K |
| 2026-09-10 | Tak Paul Peter | S-Sale | 220,866 | $2.5M |
| 2026-09-11 | Tak Paul Peter | S-Sale | 59,379 | $621K |
| 2026-09-08 | Zimmermann Martine | A-Award | 64,000 | $806K |
| 2026-09-08 | Zimmermann Martine | |||
| 2026-08-17 | Tyagarajan Seshu | S-Sale | 7,000 | $84K |
| 2026-07-06 | Sims Mark E. | A-Award | 285,000 | $2.9M |
| 2026-07-06 | Sims Mark E. | |||
| 2026-06-29 | Barone Francesca | S-Sale | 23,447 | $236K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.2M | $35.1M | $82.6M | $70.1M | $35.4M | $102.7M | $119.7M |
| Short-term Investments | $39.9M | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $45.2M | $35.1M | $84.9M | $71.9M | $36.8M | $103.8M | $119.7M |
| Property, Plant & Equipment | $425000 | $2.8M | $3.8M | $5.5M | $4.0M | $2.7M | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $45.9M | $38.3M | $89.2M | $78.5M | $41.2M | $106.9M | $125.2M |
| Accounts Payable | $218000 | $921000 | $1.6M | $380000 | $422000 | $237000 | $1.1M |
| Short-term Debt | 0 | $463000 | 0 | $464000 | $8.9M | $9.9M | $445000 |
| Total Current Liabilities | $1.4M | $4.7M | $5.4M | $5.6M | $14.2M | $37.5M | $9.0M |
| Long-term Debt | $420000 | $483000 | $560000 | $20.9M | $12.4M | $2.6M | $1.5M |
| Total Liabilities | $53.9M | $61.8M | $25.1M | $30.8M | $28.5M | $40.5M | $73.3M |
| Retained Earnings | -$26.5M | -$44.2M | -$80.3M | -$99.1M | -$137.0M | -$192.2M | -$230.4M |
| Total Equity | -$8.0M | -$23.6M | $64.1M | $47.7M | $12.7M | $66.3M | $51.9M |
| Total Debt | $420000 | $946000 | $560000 | $22.8M | $22.8M | $13.5M | $1.9M |
| Net Debt | -$44.6M | -$34.1M | -$82.1M | -$47.3M | -$12.7M | -$89.2M | -$117.8M |
| Working Capital | $43.8M | $30.4M | $79.6M | $66.3M | $22.6M | $66.3M | $110.7M |
Financial Health
| Debt / Equity | 0.39 |
| Current Ratio | 16.09 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -0.34 |
Profitability
| Return on Equity | -89.38% |
| Return on Invested Capital | -36.74% |
| Return on Assets | -42.53% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALDX · CABA · CAPR · CTNM · EDIT · GNLX · IMMP
Explore sector: Healthcare · Biotechnology
More sections of CADL: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks